About

The fourth Drug Discovery Re-Invented Meeting brings together experts in medicinal chemistry, structure-based drug design, computational chemistry, emerging drug targets, and novel technology platforms. The meeting is extremely interactive with enthusiastic question and answer sessions following each talk.  This meeting remains unique with respect to the breadth of participants and focus on new approaches to discovering drugs. With large pharma reducing investment in internal early stage research, drug pipelines will increasingly be filled by alternative sources. These players include: government, academic labs, non-profits, biotech companies, and pharmaceutical “open innovation” models.

Key Sessions

• New Approaches in Biotech, Academia, and Pharma
• New Screening Technologies and Drug Targets
• Structure, Modeling, and Fragment-based Design
• Government and Non-profit Sector in Drug Discovery and Development
• Importance of CROs in Supporting the Virtual Drug Discovery Model
• Emerging Pharmacological Targets
• Business of Biotech

Grant Opportunity

We have 3 x $1,000 grants available to students, post-docs and young faculty (first three years after start of independence), available on a first-come, first-serve basis. To apply please email your CV and abstract to Emily Bicknell. Please note that successful applicants will be required to give a short talk or poster presentation.

Student Offer

Take advantage of this fantastic opportunity for students! Register an academic at the earlybird rate of $1,822 and bring a student for only $850. Unfortunately, Postdocs are not eligible for this offer. Both registration packages include; accommodation for the 21, 22, 23 February 2019 (on a shared basis for students) and a 24hour all-inclusive food and beverage package for the conference period. Academic registrations must be completed by 17th December 2018. Once registered, please contact Emily Bicknell to obtain a special registration link for your student.

Confirmed Keynote Speaker

Michael Zasloff (Enterin Inc.)

Confirmed Invited Speakers

Denise Barbut (Enterin Inc.)
Benjamin Blass (Temple University)
'DESIGN, SYNTHESIS, AND EVALUATION OF NOVEL CYP INHIBITORS AS POTENTIAL TREATMENTS FOR METABOLIC SYNDROME'
Douglas Brenneman (Kannalife Sciences)
'CANNABINOIDS PREVENT PACLITAXEL-INDUCED TOXICITY IN DORSAL ROOT GANGLION NEURONS: MECHANISM OF ACTION'
Heather Carlson (University of Michigan)
'COSOLVENT MOLECULAR DYNAMICS SIMULATIONS'
Andrew Cole (Arbutus Bio)
'INHIBITORS OF HBV CAPSID ASSEMBLY AS AN APPROACH TO TREATING HEPATITIS B VIRUS INFECTION
Bart DeCorte (Mercachem)
'THE EVOLVING OUTSOURCING LANDSCAPE IN PHARMA R&D – PROS AND CONS OF DIFFERENT MODELS'
Vicki Feher (Schrödinger)
'TARGETING MALARIA DIHYDROOROTATE DEHYDROGENASE: THE IMPACT OF A COMPUTATIONAL ASSAY'
Brett Hall (Trans Medical Sciences)
'HUMANIZING MODELS FOR ONCOLOGY DRUG DISCOVERY'
Bryce Harrison (Morphic Therapeutics)
'THE DISCOVERY OF SOTAGLIFLOZIN AND LX2761, SGLT2/SGLT1 INHIBITORS FOR THE TREATMENT OF DIABETES'
Brian Harvey (Enterin Inc.)
'A BRIEF HISTORY OF REGULATORY TIME: FDA PAST, PRESENT & FUTURE'
Edward Hessler (Bridge Organics)
'A SCALABLE SYNTHESIS OF A KEY INTERMEDIATE FOR SQUALAMINE'
Philip Jones (MD Anderson Cancer Center)
'BENCH-AT-BEDSIDE DRUG DISCOVERY AT MD ANDERSON CANCER CENTER'
William Jorgensen (Yale University)
'EFFICIENT LEAD OPTIMIZATION GUIDED BY MODELING AND CRYSTALLOGRAPHY '
Rick Keenan (BioMotiv)
'TARGETING THE UNFOLDED PROTEIN RESPONSE - DISCOVERY OF IRE1ALPHA INHIBITORS FOR THE TREATMENT OF RETINITIS PIGMENTOSA'
John Kulp (Conifer Point)
'TARGETING RNA WITH DRUG-LIKE SMALL MOLECULES'
Stephen Martin (University of Texas at Austin)
'GAP JUMPING. USING CHEMISTRY TO ADDRESS UNMET NEEDS IN NEUROSCIENCE'
Kenneth Merz (Michigan State University)
'EXPLORATION OF MOLECULAR RECOGNITION PROCESSES'
Dean Petkanas (Kannalife Sciences)
'RAISING CAPITAL FOR SMALL DRUG DISCOVERY COMPANIES'
Theodore Price (UT Dallas / Doloromics)
'HARNESSING THE RNA SEQUENCING REVOLUTION TO FIND NEW TARGETS AND BIOMARKERS FOR PAIN DRUG DISCOVERY'
Stacey Shiigi (Intrexon)
Alex Stojanovic (The Naissos Group)
EARLY INVESTMENT IN COMMERCIAL STRATEGY PAYS DIVIDENDS: A PRIMER FOR BIOTECHS
Matt Todd (Blumberg Institute)
'EFFICIENTLY PROSECUTING LIBRARIES OF NATURAL PRODUCT EXTRACTS AT THE NPDI'
Deping Wang (Merck)
'THE IDENTIFICATION OF A NOVEL LEAD CLASS FOR PDE2 INHIBITION USING FRAGMENT BASED SCREENING'
Richard Warburg (Godney Holdings LLC)
'DRUG DEVELOPMENT THROUGH THE EYES OF PRIVATE EQUITY, INTELLECTUAL PROPERTY AND SCIENCE'
Lance Westerhoff (Quantum Bio)
'MT_SCORE: A METHOD FOR FAST FREE ENERGY BASED PROTEIN:LIGAND BINDING AFFINITY DETERMINATION USING MOVABLETYPE'
Jay Wrobel (FCCDC)
'A FEW DRUG DISCOVERY PROJECTS IN PARTNERSHIP WITH ACADEMIC RESEARCHERS'